Arabic Arabic English English French French German German
dark

 Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights

Lysogene, a gene therapy platform company targeting central nervous system diseases, announced the termination of its license agreement with Sarepta for LYS-SAF302, a phase 2/3 asset for the treatment of mucopolysaccharidosis Type IIIA, effective as of July 11, 2022. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

BridgeBio and Amgen Unite on Combination Therapy for Advanced Solid Tumors

Next Post

FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

Related Posts
Total
0
Share